Co-Diagnostics to Host Fireside Chat on November 5th with CEO, Dwight Egan, to Discuss Recently Announced Definitive Agreement in Saudi Arabia

Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) will host a virtual fireside chat on November 5, 2025 at 11:00 am ET with CEO Dwight Egan to discuss the company’s growth initiatives and its recently announced definitive agreement with Arabian Eagle to form CoMira Diagnostics in Saudi Arabia.

The discussion will cover plans to advance regional deployment of the Co-Dx PCR platform across the Middle East. A live Q&A will follow; a recording will be posted on Co-Dx investor relations. Attendees may submit questions in advance to CODX@kcsa.com. Registration is available via the provided link. The Co-Dx PCR platform remains subject to regulatory review and is not currently available for sale.

News Market Reaction

-5.17%

10 alerts

-5.17% News Effect

+9.5% Peak Tracked

-7.6% Trough Tracked

-$2M Valuation Impact

$31M Market Cap

0.1x Rel. Volume

On the day this news was published, CODX declined 5.17%, reflecting a notable negative market reaction. Argus tracked a peak move of +9.5% during that session. Argus tracked a trough of -7.6% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $31M at that time.

Data tracked by StockTitan Argus on the day of publication.

SALT LAKE CITY, Oct. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will host a virtual fireside chat on Wednesday, November 5, 2025 at 11:00 am ET.

Join Dwight Egan, CEO of Co-Dx, for an update on the Company's growth initiatives, including its recently announced definitive agreement with Arabian Eagle in the Kingdom of Saudi Arabia to form CoMira Diagnostics and to advance the regional deployment of the Co-Dx™ PCR platform* across the Middle East.

Virtual Fireside Chat Details

Date:	November 5, 2025
Time:	11:00 am ET
Registration Link:	https://shorturl.at/YZDb1

A Q&A session will take place at the end of the discussion, and a recording of the fireside chat will be available on Co-Dx's Investor Relations website following the event. To ensure your questions are addressed, please submit them in advance to CODX@kcsa.com.

*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not currently available for sale.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-to-host-fireside-chat-on-november-5th-with-ceo-dwight-egan-to-discuss-recently-announced-definitive-agreement-in-saudi-arabia-302600199.html

SOURCE Co-Diagnostics

FAQ

When is the Co-Diagnostics (CODX) fireside chat on the Saudi Arabia agreement?

The virtual fireside chat is scheduled for November 5, 2025 at 11:00 am ET.

What will Co-Diagnostics (CODX) discuss in the November 5, 2025 fireside chat?

CEO Dwight Egan will discuss growth initiatives and the definitive agreement to form CoMira Diagnostics with Arabian Eagle in Saudi Arabia.

How can investors register for the Co-Diagnostics (CODX) November 5, 2025 event?

Register using the short link provided in the announcement: https://shorturl.at/YZDb1.

Will Co-Diagnostics (CODX) answer shareholder questions during the November 5, 2025 chat?

Yes. A live Q&A will follow the discussion and you can submit questions in advance to CODX@kcsa.com.

What is the status of the Co-Dx PCR platform mentioned by Co-Diagnostics (CODX)?

The Co-Dx PCR platform is subject to regulatory review and is not currently available for sale.

Will the Co-Diagnostics (CODX) November 5, 2025 fireside chat be recorded?

Yes. A recording will be made available on Co-Dx’s investor relations website after the event.